Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Interventional 50 Observational 6 Expanded_access 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

balstilimab 2 zipalertinib 1 ulixertinib 1 tisagenlecleucel 1 telisotuzumab vedotin 1 ribociclib 1 nirogacestat 1 mirdametinib 1 mifamurtide 1 lifileucel 1 leronlimab 1 fluorodopa F 18 1 fludarabine phosphate 1 fludarabine 1 dodecyl maltoside 1 ceritinib 1 carbon-11 methionine 1 capmatinib 1 brexucabtagene autoleucel 1 Sunitinib 1 Methionine 1 Insulin Infusion Systems 1 Cyclophosphamide 1 Alpelisib 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × ribociclib × 90 days × Clear all

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Novartis

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡